Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMG 193 + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
AMG 193 + pembrolizumab is a combination therapy currently in clinical development for the treatment of advanced solid tumors, especially non-small cell lung cancer (NSCLC) with homozygous MTAP deletion. AMG 193 is an oral, CNS-penetrant, methylthioadenosine-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor that selectively induces synthetic lethality in MTAP-deleted tumor cells by robustly inhibiting PRMT5, leading to tumor cell death[1][2][4][7]. Pembrolizumab is a monoclonal antibody targeting PD-1, a checkpoint protein on T cells, and functions as a checkpoint inhibitor to enhance antitumor immune responses. The rationale for the combination is to target tumor cell survival through two mechanisms: synthetic lethality via PRMT5 inhibition (AMG 193) and immune checkpoint inhibition (pembrolizumab). The combination is being evaluated as an investigational regimen, with some study arms including additional chemotherapy agents such as carboplatin, pemetrexed, and paclitaxel[3][5]. Currently, AMG 193 + pembrolizumab is in phase I clinical trials, primarily sponsored by Amgen, and is tested for safety, tolerability, pharmacokinetics, and efficacy in metastatic or locally advanced MTAP-deleted thoracic tumors, including NSCLC[3][5][6].
- Other names
- AMG 193 + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PRMT5 (Protein arginine N-methyltransferase 5)
Beyond the preview
Go deeper on AMG 193 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMG 193 + pembrolizumab.